Tag: renal insufficiency market forecast

Uncover key drivers, emerging technologies, and competitive movements shaping the renal insufficiency market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Renal Insufficiency Market covering 2026–2035?

The renal insufficiency market has recently experienced significant expansion. It is anticipated to increase from $12.1 billion in 2025 to $13.48 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.4%. This historical growth can be attributed to factors such as the rising prevalence of diabetes and hypertension, the expansion of dialysis center networks, increased utilization of ACE inhibitors and ARBs, a growing diagnosis of chronic kidney disease, and improved access to renal care services.

The renal insufficiency market size is projected to experience swift expansion in the coming years. This market is anticipated to reach a value of $20.51 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%. The growth expected during the forecast period stems from factors such as the increasing integration of home dialysis solutions, a surge in investments towards regenerative therapies, the broader implementation of digital patient monitoring, an escalating need for individualized renal treatment strategies, and a heightened emphasis on retarding disease progression. Furthermore, key trends emerging during the forecast period encompass the greater embrace of advanced dialysis methods, a heightened focus on managing the disease in its early stages, an expanding application of combination drug therapies, a wider availability of home-based treatment alternatives, and an intensified concentration on patient-centered care approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21271&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Renal Insufficiency Market?

The rising incidence of high blood pressure and diabetes is anticipated to propel the expansion of the renal insufficiency market moving forward. These conditions, high blood pressure and diabetes, are linked to factors such as inadequate diet, insufficient physical activity, obesity, genetic predisposition, and an aging demographic. Hypertension damages kidney blood vessels through scarring and reduced filtration, while diabetes leads to thickened and overworked kidney vessels due to elevated blood sugar levels; both conditions accelerate kidney damage and ultimately result in renal insufficiency. For instance, in May 2024, according to the National Health Service, a UK-based government agency, the number of high blood pressure diagnoses in the South East increased by 71,120 patients in December 2023, marking a 5.4% rise compared to December 2022. Furthermore, in April 2023, the British Diabetic Association, a UK-based charity organization, reported that 4.3 million people are living with a diabetes diagnosis in the UK. Therefore, the growing number of high blood pressure and diabetes cases is driving the growth of the renal insufficiency market.

What Leading Segments Are Studied In The Renal Insufficiency Market?

The renal insufficiency market covered in this report is segmented –

1) By Treatment Type: Medications, Dialysis, Kidney Transplantation, Other Treatment Types

2) By Disease Stage: Chronic Kidney Disease (CKD) Stages, End-Stage Renal Disease (ESRD)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Dialysis Centers, Hospital And Clinics, Research And Academic Institutes

Subsegments:

1) By Medications: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Sodium Bicarbonate

2) By Dialysis: Hemodialysis, Peritoneal Dialysis, Home Dialysis, Continuous Renal Replacement Therapy (CRRT)

3) By Kidney Transplantation: Living Donor Kidney Transplant, Deceased Donor Kidney Transplant, Kidney Transplant Immunosuppressive Therapy

4) By Other Treatment Types: Lifestyle And Dietary Modifications, Stem Cell Therapy, Gene Therapy

Which Trends Are Shaping Activity Within The Renal Insufficiency Market?

Leading companies in the renal insufficiency market are developing glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to manage kidney and cardiovascular complications in individuals with diabetes and chronic kidney disease (CKD). These GLP-1 RAs improve glucose regulation, decrease inflammation, and reduce oxidative stress within the kidneys, thereby slowing the advancement of renal insufficiency. For example, in January 2025, Novo Nordisk, a Denmark-based pharmaceutical company, received Food and Drug Administration (FDA) approval for its Ozempic (semaglutide) to mitigate the risk of kidney disease worsening, kidney failure, and cardiovascular death in adults suffering from type 2 diabetes and chronic kidney disease (CKD). This approval underscores the increasing importance of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a combined treatment strategy for both diabetes and renal insufficiency, addressing significant unmet medical needs in patients with progressive CKD.

Which Key Players Are Driving Competition In The Renal Insufficiency Market?

Major companies operating in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/renal-insufficiency-global-market-report

Which Region Is Projected To Lead The Renal Insufficiency Market During The Forecast Period?

North America was the largest region in the renal insufficiency market in 2025. The regions covered in the renal insufficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Renal Insufficiency Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21271&type=smp

Browse Through More Reports Similar to the Global Renal Insufficiency Market 2026, By The Business Research Company

Rare Kidney Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Kidney Dialysis Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-dialysis-global-market-report

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Much Will The Renal Insufficiency Market Be Worth By 2029?

The market size for renal insufficiency has experienced swift expansion in the past few years. Its anticipated growth projection is from $10.87 billion in 2024 to $12.1 billion in 2025, indicating a compound annual growth rate (CAGR) of 11.4%. The historical growth pattern can be associated with a rising count of hypertension and diabetes cases, higher occurrence of chronic kidney disease (CKD), an increase in urinary tract obstruction cases, an aging demographic, and a surge in knowledge and consciousness about kidney health.

The market size for renal insufficiency is anticipated to expand significantly in the coming years, reaching $18.52 billion in 2029 with a CAGR of 11.2%. Predicted growth during the forecast period is due to the rise in acute kidney injuries (AKI), the popularity of home-based treatment alternatives, increasing healthcare expenses, and investment in R&D. Key trends for the upcoming period encompass progress in medical technology, continuous improvements in technology and therapy approaches, incorporating personalized medicine, advancements in dialysis techniques, and the creation of novel and innovative drugs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21271&type=smp

Which Key Factors Are Fueling Growth In The Renal Insufficiency Market?

The rise in high blood pressure and diabetes incidences are foreseen to stimulate the expansion of the renal insufficiency market in the future. Elements like unhealthy diet, physical inactivity, obesity, genetic factors, and an aging demographic result in high blood pressure and diabetes. Both conditions are known to cause significant damage to the kidneys, leading to renal insufficiency. High blood pressure scars and reduces kidney blood vessel filtration, and high blood sugar due to diabetes thickens and overworks kidney vessels, consequently speeding the process of kidney damage. For example, the National Health Service, a governmental agency in the UK, revealed in May 2024 that the South East saw a surge in high blood pressure diagnoses by 71,120 patients – a 5.4% increase – in December 2023 compared to the same month the previous year. Also, the British Diabetic Association, a charity in the UK, reported in April 2023 that 4.3 million people in the UK are diagnosed with diabetes. With these rising numbers, the growth of the renal insufficiency market is fuelled by the escalating instances of high blood pressure and diabetes.

Which Segmentation Factors Are Critical In The Renal Insufficiency Market Analysis?

The renal insufficiencymarket covered in this report is segmented –

1) By Treatment Type: Medications; Dialysis; Kidney Transplantation; Other Treatment Types

2) By Disease Stage: Chronic Kidney Disease (CKD) Stages; End-Stage Renal Disease (ESRD)

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

4) By End-User: Dialysis Centers; Hospital And Clinics; Research And Academic Institutes

Subsegments:

1) By Medications: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Diuretics; Erythropoiesis-Stimulating Agents (ESAs); Phosphate Binders; Sodium Bicarbonate

2) By Dialysis: Hemodialysis; Peritoneal Dialysis; Home Dialysis; Continuous Renal Replacement Therapy (CRRT)

3) By Kidney Transplantation: Living Donor Kidney Transplant; Deceased Donor Kidney Transplant; Kidney Transplant Immunosuppressive Therapy

4) By Other Treatment Types: Lifestyle And Dietary Modifications; Stem Cell Therapy; Gene Therapy

What New Opportunities Are Emerging From Trends In The Renal Insufficiency Market?

Major companies in the renal insufficiency market are focusing on the development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to manage renal and cardiovascular complications in patients suffering from diabetes and chronic kidney disease (CKD). GLP-1 RAs help improve glucose regulation, decrease inflammation, and reduce oxidative stress in the kidneys, thereby slowing renal insufficiency progression. For example, in January 2025, Novo Nordisk, a pharmaceutical firm based in Denmark, received approval from the Food and Drug Administration (FDA) for Ozempic (semaglutide) to lower the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD. This approval underscores the increasing focus on GLP-1 RAs as a dual therapeutic strategy for managing both diabetes and renal insufficiency, addressing significant unmet needs in patients with advancing CKD.

Which Players Are Shaping The Competitive Landscape Of The Renal Insufficiency Market?

Major companies operating in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation, Sorin Group.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/renal-insufficiency-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Renal Insufficiency Market?

North America was the largest region in the renal insufficiency market in 2024. The regions covered in the renal insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21271&type=smp

Browse Through More Reports Similar to the Global Renal Insufficiency Market 2025, By The Business Research Company

End Stage Renal Disease Esrd Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

Hepatorenal Syndrome Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-treatment-global-market-report

Renal Denervation Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-denervation-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Renal Insufficiency Industry Expected To Reach By 2029, Starting From 2025 Levels?

The renal insufficiency market has seen swift expansion in recent years. Its size is expected to increase from $10.87 billion in 2024 to $12.1 billion in 2025, progressing at a compound annual growth rate (CAGR) of 11.4%. The contributing factors to this growth historically include a rise in high blood pressure and diabetes cases, the increasing prevalence of chronic kidney disease (CKD), a growing incidence of urinary tract obstructions, an aging population, and enhanced awareness and education regarding kidney health.

The renal insufficiency market size is projected to experience substantial growth over the coming years, with expectations to reach $18.52 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 11.2%. This projected expansion during the forecast period is primarily driven by the increasing incidence of acute kidney injuries (AKI), the growing acceptance of home-based treatment options, a significant rise in healthcare expenditure, and increased investments in research and development. Key trends anticipated in this period include advancements in medical technology, improvements in technology and treatment options, the integration of personalized medicine approaches, further advancements in dialysis technology, and the creation of novel and innovative medications.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21271&type=smp

What Are The Drivers Pushing New Developments In The Renal Insufficiency Market?

The rising incidence of high blood pressure and diabetes cases is projected to fuel the expansion of the renal insufficiency market in the coming years. These conditions are linked to factors such as poor dietary habits, insufficient physical activity, obesity, genetic predispositions, and an aging population. Elevated blood pressure harms kidney blood vessels through scarring and diminished filtration, while diabetes causes kidney vessels to thicken and become overworked due to high blood sugar levels. Both conditions consequently hasten kidney deterioration, culminating in renal insufficiency. As an illustration, in May 2024, the National Health Service, a UK government body, reported that in December 2023, high blood pressure diagnoses in the South East rose by 71,120 patients, signifying a 5.4% increase from December 2022. Moreover, in April 2023, according to the British Diabetic Association, a UK-based charity, 4.3 million individuals in the UK are living with a diabetes diagnosis. Consequently, the growing number of high blood pressure and diabetes diagnoses is powering the growth of the renal insufficiency market.

What Are The Major Segments Identified In The Renal Insufficiency Market?

The renal insufficiencymarket covered in this report is segmented –

1) By Treatment Type: Medications; Dialysis; Kidney Transplantation; Other Treatment Types

2) By Disease Stage: Chronic Kidney Disease (CKD) Stages; End-Stage Renal Disease (ESRD)

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

4) By End-User: Dialysis Centers; Hospital And Clinics; Research And Academic Institutes

Subsegments:

1) By Medications: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Diuretics; Erythropoiesis-Stimulating Agents (ESAs); Phosphate Binders; Sodium Bicarbonate

2) By Dialysis: Hemodialysis; Peritoneal Dialysis; Home Dialysis; Continuous Renal Replacement Therapy (CRRT)

3) By Kidney Transplantation: Living Donor Kidney Transplant; Deceased Donor Kidney Transplant; Kidney Transplant Immunosuppressive Therapy

4) By Other Treatment Types: Lifestyle And Dietary Modifications; Stem Cell Therapy; Gene Therapy

Which Trends Are Impacting The Renal Insufficiency Market?

Leading firms within the renal insufficiency market are creating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) aimed at managing renal and cardiovascular issues in individuals suffering from diabetes and chronic kidney disease (CKD). These GLP-1 RAs work by enhancing glucose regulation, decreasing inflammation, and mitigating oxidative stress in the kidneys, which in turn decelerates the advancement of renal insufficiency. For instance, in January 2025, Novo Nordisk, a Denmark-based pharmaceutical company, secured Food and Drug Administration (FDA) approval for its medication Ozempic (semaglutide). This approval specifically targets the reduction of worsening kidney disease, kidney failure, and cardiovascular death risks in adults diagnosed with type 2 diabetes and chronic kidney disease (CKD). This significant approval underscores the increasing focus on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a comprehensive strategy for simultaneously treating diabetes and renal insufficiency, thereby fulfilling crucial unmet needs for patients experiencing progressive CKD.

Which Major Firms Are Strengthening Their Position In The Renal Insufficiency Industry?

Major companies operating in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation, Sorin Group.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/renal-insufficiency-global-market-report

What Are The Regional Market Dynamics Impacting The Renal Insufficiency Industry?

North America was the largest region in the renal insufficiency market in 2024. The regions covered in the renal insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Renal Insufficiency Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21271&type=smp

Browse Through More Reports Similar to the Global Renal Insufficiency Market 2025, By The Business Research Company

End Stage Renal Disease Esrd Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

Hepatorenal Syndrome Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-treatment-global-market-report

Renal Denervation Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-denervation-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Renal Insufficiency Market In 2029?

The market for renal insufficiency has seen a swift expansion in recent times. Predictions show it evolving from a worth of $10.87 billion in 2024, to attain a valuation of $12.1 billion in 2025, signaling a compound annual growth rate (CAGR) of 11.4%. The historical growth trajectory can be traced back to increased incidents of hypertension and diabetes, escalating diagnosis rates of chronic kidney disease (CKD), a higher occurrence of obstructions in the urinary system, an aging demographic, coupled with a rising consciousness and knowledge about kidney wellness.

The market size of renal insufficiency is projected to significantly expand in the upcoming years, reaching$18.52 billion by 2029 with a compound annual growth rate (CAGR) of 11.2%. This anticipated growth within the projection period can be linked to a rise in cases of acute kidney injuries (AKI), increased preference for home-based treatment alternatives, escalation in healthcare spending, and investments in research and development. Dominant trends for the forecasting period comprise progress in medical technology, further advancement in treatment methods and technology, the inclusion of personalized medicine, developments in dialysis technology, and the creation of innovative and new medications.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21271&type=smp

Which Factors and External Forces Are Driving Demand in the Renal Insufficiency Market?

The renal insufficiency market can expect to see growth, given the rising frequency of high blood pressure and diabetes diagnoses. Factors such as poor nutrition, insufficient physical exercise, obesity, genetic susceptibility, and an aging populace contribute to these health conditions. Both high blood pressure and diabetes can result in kidney damage, with high blood pressure leading to scarred, less functional kidney blood vessels, and diabetes causing thickened and strained kidney vessels due to elevated blood sugar. Take, for example, the data from December 2023, released by the National Health Service in the UK in May 2024, which showed an increase in high blood pressure diagnoses in the South East by 71,120 patients — a 5.4% increase compared to the previous year. The British Diabetic Association also reported in April 2023 that there were 4.3 million people with a diabetes diagnosis in the UK. As such, the surge of high blood pressure and diabetes cases is contributing to the expansion of the renal insufficiency market.

Which Segments in the Renal Insufficiency Offer the Most Growth?

The renal insufficiencymarket covered in this report is segmented –

1) By Treatment Type: Medications; Dialysis; Kidney Transplantation; Other Treatment Types

2) By Disease Stage: Chronic Kidney Disease (CKD) Stages; End-Stage Renal Disease (ESRD)

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

4) By End-User: Dialysis Centers; Hospital And Clinics; Research And Academic Institutes

Subsegments:

1) By Medications: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Diuretics; Erythropoiesis-Stimulating Agents (ESAs); Phosphate Binders; Sodium Bicarbonate

2) By Dialysis: Hemodialysis; Peritoneal Dialysis; Home Dialysis; Continuous Renal Replacement Therapy (CRRT)

3) By Kidney Transplantation: Living Donor Kidney Transplant; Deceased Donor Kidney Transplant; Kidney Transplant Immunosuppressive Therapy

4) By Other Treatment Types: Lifestyle And Dietary Modifications; Stem Cell Therapy; Gene Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21271&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Renal Insufficiency Market?# Market?

North America was the largest region in the renal insufficiency market in 2024. The regions covered in the renal insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theRenal Insufficiency Market’s Growth?

The renal insufficiency market is seeing a surge in the development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) by major companies. These innovations address renal and cardiovascular complications in individuals suffering from diabetes and chronic kidney disease (CKD). GLP-1 RAs aid in controlling glucose, reducing inflammation, and minimizing oxidative stress in kidneys, which in turn decelerates the progress of renal insufficiency. In January 2025, an example of such advancement was seen when the Denmark-based pharmaceutical firm, Novo Nordisk, was granted approval by the Food and Drug Administration (FDA) for Ozempic (semaglutide). This product reduces the risk of kidney failure, worsening kidney disease, and cardiovascular mortality in adults with type 2 diabetes and CKD. This accreditation underscores the increased focus on GLP-1 RAs as a comprehensive strategy to tackle diabetes and renal insufficiency concurrently, addressing pressing needs in patients with advanced CKD.

View the full report here:

https://www.thebusinessresearchcompany.com/report/renal-insufficiency-global-market-report

What Are the Key Elements That Define the Renal Insufficiency Market?

Renal insufficiency refers to the reduced ability of the kidneys to filter waste products and maintain fluid and electrolyte balance in the body. It can result from chronic conditions such as diabetes, hypertension, or acute kidney injury, leading to the accumulation of toxins in the blood. If left untreated, renal insufficiency may progress to chronic kidney disease (CKD) or kidney failure, requiring dialysis or transplantation.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21271

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Renal Insufficiency Market?

The market size for renal insufficiency has been rapidly expanding of late. The market, valued at $10.87 billion in 2024, is expected to rise up to $12.14 billion in 2025, projecting a compound annual growth rate (CAGR) of 11.7%. This surge can be attributed to the growing incidences of hypertension and diabetes, an increased number of chronic kidney disease (CKD) cases, an uptick in urinary tract obstructions, an aging demographic, and heightened awareness and education concerning kidney health.

What Growth Rate Is Forecasted for the Renal Insufficiency Market by 2029?

In the coming years, the renal insufficiency market is anticipated to witness swift expansion, reaching a valuation of $18.68 billion in 2029, with a compound annual growth rate (CAGR) of 11.4%. Several factors contribute to this projected growth during the forecast period: the rising incidence of acute kidney injuries (AKI), the growing acceptance of home-based treatment options, increased healthcare spending, and investment in research and development. Expected trends for this period include breakthroughs in medical and treatment technologies, incorporation of personalized medicine, progress in dialysis technology, and the introduction of innovative drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21271&type=smp

Which Key Companies Are Shaping the Future of the Renal Insufficiency Market?

Major companies operating in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation, Sorin Group.

Which Factors Are Driving Demand in the Renal Insufficiency Industry?

The growth of the renal insufficiency market is anticipated to be driven by the escalating number of diabetes and high blood pressure cases. These health issues stem from factors such as improper diet, insufficient physical exercise, obesity, hereditary predisposition, and an aging populace. High blood pressure leads to scarring and decreased filtration in kidney blood vessels, while high blood sugar in diabetes thickens and overworks the kidney vessels, hastening kidney damage and consequentially triggering renal insufficiency. For instance, the National Health Service, a UK-based government agency, reported in May 2024, that the number of patients diagnosed with high blood pressure in the South East increased by 71,120 or 5.4% in December 2023 compared to the same month in 2022. Additionally, as per the British Diabetic Association, a UK-based charity organization data from April 2023, 4.3 million individuals in the UK live with a diabetes diagnosis. As a result, the surge in high blood pressure and diabetes cases is fueling the progression of the renal insufficiency market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21271&type=smp

How Is the Renal Insufficiency Market Segmented by Several Divisions?

The renal insufficiency market covered in this report is segmented –

1) By Treatment Type: Medications, Dialysis, Kidney Transplantation, Other Treatment Types

2) By Disease Stage: Chronic Kidney Disease (CKD) Stages, End-Stage Renal Disease (ESRD)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Dialysis Centers, Hospital And Clinics, Research And Academic Institutes

Subsegments:

1) By Medications: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Sodium Bicarbonate

2) By Dialysis: Hemodialysis, Peritoneal Dialysis, Home Dialysis, Continuous Renal Replacement Therapy (CRRT)

3) By Kidney Transplantation: Living Donor Kidney Transplant, Deceased Donor Kidney Transplant, Kidney Transplant Immunosuppressive Therapy

4) By Other Treatment Types: Lifestyle And Dietary Modifications, Stem Cell Therapy, Gene Therapy

What are the Emerging Market Trends Driving the Growth of the Renal Insufficiency Industry?

Key players in the renal insufficiency market are focusing on developing glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This is aimed at managing both renal and cardiovascular complications in patients suffering from diabetes and chronic kidney disease (CKD). GLP-1 RAs work by improving glucose control, mitigating inflammation, and reducing oxidative stress on the kidneys, which slows the development of renal insufficiency. A prime example came in January 2025, when Danish pharmaceutical firm Novo Nordisk received approval from the Food and Drug Administration (FDA) for Ozempic (semaglutide), a drug aimed at diminishing the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with CKD and type 2 diabetes. This approval underscores the increasing focus on GLP-1 RAs as a dual solution for managing diabetes and renal insufficiency, catering to significant unmet needs in patients with advancing CKD.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/renal-insufficiency-global-market-report

Which Regions Are Driving Growth in the Renal Insufficiency Market?

North America was the largest region in the renal insufficiency market in 2024. The regions covered in the renal insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21271

This Report Delivers Insight On:

1. How big is the renal insufficiency market, and how is it changing globally?

2. Who are the major companies in the renal insufficiency market, and how are they performing?

3. What are the key opportunities and risks in the renal insufficiency market right now?

4. Which products or customer segments are growing the most in the renal insufficiency market?

5. What factors are helping or slowing down the growth of the renal insufficiency market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Renal Insufficiency Market?

The market size for renal insufficiency has been rapidly expanding of late. The market, valued at $10.87 billion in 2024, is expected to rise up to $12.14 billion in 2025, projecting a compound annual growth rate (CAGR) of 11.7%. This surge can be attributed to the growing incidences of hypertension and diabetes, an increased number of chronic kidney disease (CKD) cases, an uptick in urinary tract obstructions, an aging demographic, and heightened awareness and education concerning kidney health.

What Growth Rate Is Forecasted for the Renal Insufficiency Market by 2029?

In the coming years, the renal insufficiency market is anticipated to witness swift expansion, reaching a valuation of $18.68 billion in 2029, with a compound annual growth rate (CAGR) of 11.4%. Several factors contribute to this projected growth during the forecast period: the rising incidence of acute kidney injuries (AKI), the growing acceptance of home-based treatment options, increased healthcare spending, and investment in research and development. Expected trends for this period include breakthroughs in medical and treatment technologies, incorporation of personalized medicine, progress in dialysis technology, and the introduction of innovative drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21271&type=smp

Which Key Companies Are Shaping the Future of the Renal Insufficiency Market?

Major companies operating in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation, Sorin Group.

Which Factors Are Driving Demand in the Renal Insufficiency Industry?

The growth of the renal insufficiency market is anticipated to be driven by the escalating number of diabetes and high blood pressure cases. These health issues stem from factors such as improper diet, insufficient physical exercise, obesity, hereditary predisposition, and an aging populace. High blood pressure leads to scarring and decreased filtration in kidney blood vessels, while high blood sugar in diabetes thickens and overworks the kidney vessels, hastening kidney damage and consequentially triggering renal insufficiency. For instance, the National Health Service, a UK-based government agency, reported in May 2024, that the number of patients diagnosed with high blood pressure in the South East increased by 71,120 or 5.4% in December 2023 compared to the same month in 2022. Additionally, as per the British Diabetic Association, a UK-based charity organization data from April 2023, 4.3 million individuals in the UK live with a diabetes diagnosis. As a result, the surge in high blood pressure and diabetes cases is fueling the progression of the renal insufficiency market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21271&type=smp

How Is the Renal Insufficiency Market Segmented by Several Divisions?

The renal insufficiency market covered in this report is segmented –

1) By Treatment Type: Medications, Dialysis, Kidney Transplantation, Other Treatment Types

2) By Disease Stage: Chronic Kidney Disease (CKD) Stages, End-Stage Renal Disease (ESRD)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Dialysis Centers, Hospital And Clinics, Research And Academic Institutes

Subsegments:

1) By Medications: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Sodium Bicarbonate

2) By Dialysis: Hemodialysis, Peritoneal Dialysis, Home Dialysis, Continuous Renal Replacement Therapy (CRRT)

3) By Kidney Transplantation: Living Donor Kidney Transplant, Deceased Donor Kidney Transplant, Kidney Transplant Immunosuppressive Therapy

4) By Other Treatment Types: Lifestyle And Dietary Modifications, Stem Cell Therapy, Gene Therapy

What are the Emerging Market Trends Driving the Growth of the Renal Insufficiency Industry?

Key players in the renal insufficiency market are focusing on developing glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This is aimed at managing both renal and cardiovascular complications in patients suffering from diabetes and chronic kidney disease (CKD). GLP-1 RAs work by improving glucose control, mitigating inflammation, and reducing oxidative stress on the kidneys, which slows the development of renal insufficiency. A prime example came in January 2025, when Danish pharmaceutical firm Novo Nordisk received approval from the Food and Drug Administration (FDA) for Ozempic (semaglutide), a drug aimed at diminishing the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with CKD and type 2 diabetes. This approval underscores the increasing focus on GLP-1 RAs as a dual solution for managing diabetes and renal insufficiency, catering to significant unmet needs in patients with advancing CKD.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/renal-insufficiency-global-market-report

Which Regions Are Driving Growth in the Renal Insufficiency Market?

North America was the largest region in the renal insufficiency market in 2024. The regions covered in the renal insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21271

This Report Delivers Insight On:

1. How big is the renal insufficiency market, and how is it changing globally?

2. Who are the major companies in the renal insufficiency market, and how are they performing?

3. What are the key opportunities and risks in the renal insufficiency market right now?

4. Which products or customer segments are growing the most in the renal insufficiency market?

5. What factors are helping or slowing down the growth of the renal insufficiency market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model